Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01422629
Recruitment Status : Completed
First Posted : August 24, 2011
Last Update Posted : April 9, 2014
Information provided by (Responsible Party):

Brief Summary:

This study is a multicentre, open, uncontrolled trial for the observation of histological changes in breast fibroadenoma following high intensity focused ultrasound (HIFU).

This study will be conducted in France in 20 patients with breast fibroadenoma with indication for a surgical resection. The patient will receive an HIFU treatment and 6 months after treatment, the need of the surgery is evaluated.

Condition or disease Intervention/treatment Phase
Breast Fibroadenoma Device: Ultrasonic ablation device Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma: a Feasibility Study. A Multicentric, Open, Uncontrolled Study
Study Start Date : October 2011
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Arm Intervention/treatment
Experimental: High Intensity Focused Ultrasound (HIFU) Device: Ultrasonic ablation device
High Intensity focused ultrasound treatment
Other Name: TH-One

Primary Outcome Measures :
  1. HIFU induced tissue necrosis assessed by histology of excised gland or reduction volume of fibroadenoma [ Time Frame: 6 months after HIFU treatment ]

Secondary Outcome Measures :
  1. Volume reduction of the fibroadenoma [ Time Frame: 12 months after HIFU treatment ]
    reduction in volume at 2, 4, 6 and 12 months after HIFU session or total regression of the fibroadenoma evaluated with ultrasound just before surgery

  2. - Pain score during the HIFU treatment evaluated by the Visual Analog Scale. [ Time Frame: at treatment ]
  3. Percentage of patients with Adverse events [ Time Frame: at 12 months follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of breast fibroadenoma based on:Clinical examination, Ultrasound image and mammogram for women older than 35 years, and histology
  • Fibroadenoma size superior at 1 cm at its largest dimension (measured by Ultrasound)

Exclusion Criteria:

  • Patient pregnant or lactating
  • Microcalcifications within the lesion at the mammogram.
  • History of breast cancer or history of laser or radiation therapy to the target breast
  • Breast implant in the target breast.
  • Fibroadenoma not clearly visible on the ultrasound images (in B mode)
  • Patient participating in other trials using drugs or devices

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01422629

Layout table for location information
Hôpital Jeanne de Flandre, CHU de Lille 2 Avenue Oscar Lambret
Lille, France, 59000
Hôpital Américain de Paris
Neuilly Sur Seine, France, 92200
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Loïc BOULANGER, MD Hôpital Jeanne de Flandre, CHU de Lille - FRANCE
Layout table for additonal information
Responsible Party: Theraclion Identifier: NCT01422629    
Other Study ID Numbers: HIFU/F/FA/Dec2010
First Posted: August 24, 2011    Key Record Dates
Last Update Posted: April 9, 2014
Last Verified: April 2014
Keywords provided by Theraclion:
Breast Fibroadenoma
High Intensity Focused Ultrasound
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Fibroepithelial
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial